TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06950034: A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Sponsor: Solu Therapeutics, Inc · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 105 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$6,440,280

Rescue Site Savings

+$4,241,160

Unlock Full NCT06950034 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06950034 Rescue Dossier →